Sarepta Therapeutics, Inc. (Nasdaq: SRPT) entered into a Clinical Trial Agreement (CTA) with the National Institute of Allergy and Infectious ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE